NuVasive (NASDAQ:NUVA) is scheduled to be releasing its earnings data after the market closes on Wednesday, February 7th. Analysts expect NuVasive to post earnings of $0.67 per share for the quarter.
NuVasive (NUVA) opened at $49.96 on Wednesday. The company has a current ratio of 2.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $2,580.00, a price-to-earnings ratio of 41.98, a price-to-earnings-growth ratio of 1.45 and a beta of 0.77. NuVasive has a 52-week low of $48.41 and a 52-week high of $81.68.
NuVasive declared that its Board of Directors has approved a stock repurchase plan on Tuesday, October 24th that permits the company to buyback $100.00 million in shares. This buyback authorization permits the medical device company to reacquire shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company’s management believes its stock is undervalued.
Several brokerages have commented on NUVA. Needham & Company LLC raised NuVasive from an “underperform” rating to a “buy” rating and set a $71.00 price objective for the company in a research report on Thursday, January 4th. Zacks Investment Research raised NuVasive from a “sell” rating to a “hold” rating in a research report on Tuesday, December 19th. BidaskClub raised NuVasive from a “sell” rating to a “hold” rating in a research report on Friday, December 15th. BMO Capital Markets reissued a “buy” rating and set a $70.00 price objective on shares of NuVasive in a research report on Thursday, December 14th. Finally, BTIG Research set a $74.00 price target on NuVasive and gave the stock a “buy” rating in a research report on Wednesday, December 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and thirteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $72.33.
TRADEMARK VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/31/nuvasive-nuva-to-release-earnings-on-wednesday.html.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.